Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $690,700.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $69.07, for a total transaction of $690,700.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $53,030,564.60. The trade was a 1.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00.
• On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.19, for a total transaction of $691,900.00.
• On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $71.75, for a total transaction of $1,435,000.00.
• On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.50, for a total transaction of $635,000.00.
• On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $71.53 on Friday. The company has a market capitalization of $8.48 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 0.30 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The company has a 50-day simple moving average of $66.79 and a 200 day simple moving average of $68.74. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. Halozyme Therapeutics’s revenue was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on HALO shares. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday. UBS Group reiterated a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Alpine Woods Capital Investors LLC acquired a new position in Halozyme Therapeutics during the 1st quarter worth approximately $281,000. Glenmede Trust Co. NA increased its position in Halozyme Therapeutics by 22.4% during the 1st quarter. Glenmede Trust Co. NA now owns 146,717 shares of the biopharmaceutical company’s stock worth $9,482,000 after purchasing an additional 26,851 shares in the last quarter. Argent Capital Management LLC increased its position in Halozyme Therapeutics by 52.2% during the 1st quarter. Argent Capital Management LLC now owns 9,054 shares of the biopharmaceutical company’s stock worth $585,000 after purchasing an additional 3,104 shares in the last quarter. BankChampaign National Association acquired a new position in Halozyme Therapeutics during the 1st quarter worth approximately $228,000. Finally, Western Wealth Management LLC acquired a new position in Halozyme Therapeutics during the 1st quarter worth approximately $229,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised Halozyme’s earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, signaling confidence in the company’s longer-term profit growth. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several individual quarters in 2027, reinforcing a constructive earnings outlook for Halozyme Therapeutics. Halozyme Therapeutics article
• Neutral Sentiment: One near-term forecast was trimmed slightly and another was revised lower, but the overall analyst tone remains mostly favorable. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider selling by the CEO was disclosed, but the trades were executed under a pre-arranged trading plan, which typically lessens investor concern. Halozyme Therapeutics article

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.